These are the comments in the Annual report re the research...

These are the comments in the Annual report re the research instrument and come after the a review of the company by the current management after it took over from May this year. The pre-clinical business has been revamped as part of that process so maybe it would be a good idea to wait and see what the outcome is, you won`t have long to wait as the launch or maybe re-launch will happen in 2016, probably this month at or before the AGM (my guess). Stay calm everyone.


Near Term Strategy – 2016/17

The Company has identified three key pillars to its current business model:


Sales of the second-generation pre-clinical research product This will include:

Securing sales from the existing customer base of the predecessor model;


Pursuing established distribution channels; and

Developing new distribution channels including direct sales and the appointment of new distributors.

To ensure results will be achieved, the Company announced the appointment of a General Manager - Pre-clinical Research Products to provide dedicated focus in this area.

The second generation pre-clinical research product has been improved and is planned to be launched in 2016.

This product will deliver a significant improvement to the existing technology offering in the research market. It is expected that the new product range will secure a significant share of the global market after launch.